Disc Medicine (IRON) Free Cash Flow (2020 - 2026)
Disc Medicine's (IRON) quarterly Free Cash Flow came in at -$62.2 million in Q1 2026, down 47.38% year-on-year from -$118.3 million in Q1 2025, and down 43.67% on a QoQ basis from -$43.3 million in Q4 2025.
Disc Medicine (IRON) Free Cash Flow (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has 7 years of Free Cash Flow data on file, last reported at -$62.2 million in Q1 2026.
- On a quarterly basis, Free Cash Flow fell 47.38% year-over-year to -$62.2 million in Q1 2026; TTM through Mar 2026 was -$201.3 million, a 95.49% decrease from a year earlier, with the FY2025 full-year figure at -$181.3 million, down 92.02% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$62.2 million, down from -$43.3 million in the prior quarter.
- Over the last five years, Free Cash Flow for IRON reached as high as -$7.5 million in Q3 2023 and fell as low as -$62.2 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$26.7 million across 5 years, with a median of -$17.8 million in 2023.
- Across the five-year window, Free Cash Flow surged 41.59% in 2022 and slumped 211.59% in 2025, its largest moves.
- Year by year, Free Cash Flow stood at -$9.7 million in 2022, then slumped by 83.93% to -$17.8 million in 2023, then slumped by 57.44% to -$28.0 million in 2024, then slumped by 54.59% to -$43.3 million in 2025, then tumbled by 43.67% to -$62.2 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were -$62.2 million in Q1 2026, -$43.3 million in Q4 2025, and -$47.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Disc Medicine | 2.90 Bn | 2.90 Bn | - | -62.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.24 Mn |
| Mar 31, 2026 | -62.24 Mn |
| Dec 31, 2025 | -43.32 Mn |
| Dec 31, 2025 | -43.32 Mn |
| Sep 30, 2025 | -47.83 Mn |
| Sep 30, 2025 | -47.83 Mn |
| Jun 30, 2025 | -47.95 Mn |
| Jun 30, 2025 | -47.95 Mn |
| Mar 31, 2025 | -42.23 Mn |
| Mar 31, 2025 | -42.23 Mn |
| Dec 31, 2024 | -28.02 Mn |
| Dec 31, 2024 | -28.02 Mn |
| Sep 30, 2024 | -17.35 Mn |
| Sep 30, 2024 | -17.35 Mn |
| Jun 30, 2024 | -15.39 Mn |
| Jun 30, 2024 | -15.39 Mn |
| Mar 31, 2024 | -33.67 Mn |
| Mar 31, 2024 | -33.67 Mn |
| Dec 31, 2023 | -17.80 Mn |
| Dec 31, 2023 | -17.80 Mn |